Treatment and secondary prevention of venous thromboembolism in cancer patients: Current strategies and new therapeutic options

Hamostaseologie

Volumn 32, Issue 2, 2012, Pages 139-144

  Ay, Cihan ^a   Pabinger, I ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anti coagulation; Cancer; Secondary prevention; Secondary prophylaxis; Treatment; Venous thromboembolism

Indexed keywords

ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN; DALTEPARIN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; THROMBIN; TINZAPARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; CANCER PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; REVIEW; SECONDARY PREVENTION; THROMBOSIS PREVENTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; NEOPLASM; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HUMANS; NEOPLASMS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84866182426     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1168     Document Type: Review

References (32)

1. Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815.
2. Chew HK, Wun T, Harvey D et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-464.
3. Sousou T, Khorana A. Identifying cancer patients at risk for venous thromboembolism. Hämostaseologie 2009;29:121-124.
4. Levitan N, Dowlati A, Remick SC et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-291.
5. Ay C, Dunkler D, Simanek R et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the vienna cancer and thrombosis study. J Clin Oncol 2011;29:2099-2103.
6. Khorana AA, Francis CW, Culakova E et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632-634.
7. Heit JA, O'Fallon WM, Petterson TM et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:1245-1248.
8. Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488.
9. Kearon C, Kahn SR, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008;133 (6 Suppl):454S-545S.
10. Weitz JI, Hirsh J, Samama MM, Physicians ACoC. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest. 2008;133 (6 Suppl):234S-256S.
11. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010;115:15-20.
12. Erkens PM, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2010:CD001100.
13. Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-5505.
14. Mandalà M, Falanga A, Roila F, Group EGW. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management. Ann Oncol 2010;21 (Suppl 5):v274-v276.
15. Khorana AA, Streiff MB, Farge D et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009;27:4919-4926.
16. Streiff MB. Diagnosis and initial treatment of venous thromboembolism in patients with cancer. J Clin Oncol 2009;27:4889-4894.
17. Kim HS, Preece SR, Black JH et al. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vasc Surg 2008;47:388-394.
18. Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-3083.
19. Lee AY, Levine MN, Baker RI et al. Low-molecularweight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.
20. Meyer G, Marjanovic Z, Valcke J et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-1735.
21. Hull RD, Pineo GF, Brant RF et al. Long-term lowmolecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062-1072.
22. Deitcher SR, Kessler CM, Merli G et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12:389-396.
23. Lee AY. Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J Clin Oncol 2009;27:4895-4901.
24. Khorana AA. Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol 2009;20:1619-1630.
25. Akl EA, Barba M, Rohilla S et al. Low-molecularweight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res 2008;27:21.
26. Bauersachs RM. New anticoagulants. Hämostaseologie 2008;28:21-26.
27. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-2352.
28. Schulman S, Kearon C, Haemostasis SoCoAotSaSCotISoTa. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-694.
29. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-2510.
30. Levine MN. New antithrombotic drugs: potential for use in oncology. J Clin Oncol 2009;27:4912-4918.
31. Carrier M, Le Gal G, Cho R et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009;7:760-765.
32. Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hämo staseologie 2012;32:115-125.